Clinical Trial Update: Efficacy of FLUTIFORM ® vs Seretide® in Moderate to Severe Persistent Asthma in Subjects Aged ≥12 Years [Phase 3]

View source ↗

Summary

Phase 3 trial assessing efficacy of FLUTIFORM versus Seretide in moderate to severe persistent asthma in individuals aged 12 and older.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• FlutiForm (fluticasone propionate/formoterol)
• Seretide (fluticasone propionate/salmeterol)

Snippet

Sponsor: Mundipharma (China) Pharmaceutical Co. Ltd | Conditions: Asthma | Phase 3 | Status: UNKNOWN